Stefano Molica, MD, is a consultant in the Haematology department at Castle Hill Hospital, Hull, and an Honorary Professor of Hull York University. He is a member of the American Society of Clinical Oncology (ASCO), the American Society of Hematology (ASH), and the European Society of Hematology, and he was actively involved in the GIMEMA (Gruppo Italiano Malattie Ematologiche Adulto) lymphoproliferative working group from 2010 to 2021. His current research focuses on investigating the impact of novel laboratory parameters useful for assessing the prognosis of CLL and studying the role of novel agents in such a disease. He has published 254 peer-reviewed papers, primarily in the field of CLL and CLL-related disorders. He is a member of the editorial board of Leukemia and Lymphoma, Cancers, BMC Medicine, ISRN Hematology, and the International Journal of Haematological Oncology. He currently serves as a referee for several hematology–oncology journals.